Collectively, these results indicate that Cpt1a-deficient cells rely on Nrf2 to promote glucose consumption, revealing a metabolic vulnerability that can be exploited by pharmacological or genetic targeting of these pathways in breast cancers. Here, NFE2L2 is linked to breast carcinoma.